Eqis Capital Management, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Eqis Capital Management, Inc.
- $1.19 Billion
- Q1 2024
A detailed history of Eqis Capital Management, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 17,448 shares of CPRX stock, worth $267,128. This represents 0.02% of its overall portfolio holdings.
Number of Shares
17,448Holding current value
$267,128% of portfolio
0.02%Shares
6 transactions
Others Institutions Holding CPRX
# of Institutions
277Shares Held
95.7MCall Options Held
40.6KPut Options Held
67.2K-
Black Rock Inc. New York, NY17.7MShares$271 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$140 Million3.01% of portfolio
-
State Street Corp Boston, MA8.15MShares$125 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.98MShares$122 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.74MShares$41.9 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $1.57B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...